A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. (Q33404541)

26 July 2017

title

A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. (English)

1 reference

26 July 2017

main subject

dasatinib monohydrate

1 reference

1 reference

12

Razelle Kurzrock

1 reference

26 July 2017

Sarina Piha-Paul

6

0 references

Aung Naing

3

object named as

Aung Naing

1 reference

26 July 2017

5

Gerald S Falchook

1 reference

26 July 2017

4

Jennifer J Wheler

1 reference

26 July 2017

7

Stacy L Moulder

1 reference

26 July 2017

David S Hong

1

1 reference

26 July 2017

Jennifer Hsing Choe

2

1 reference

26 July 2017

Goldy C George

8

1 reference

26 July 2017

Jonathan M Choe

9

1 reference

26 July 2017

Lewis C Strauss

10

1 reference

26 July 2017

Gary E Gallick

11

1 reference

26 July 2017

publication date

20 November 2012

1 reference

Investigational New Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

31

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

918-926

1 reference

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

A phase 2 trial of dasatinib in advanced melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Src: a potential target for the treatment of triple-negative breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Cancer therapy beyond apoptosis: autophagy and anoikis as mechanisms of cell death

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Gemcitabine-associated hemolytic-uremic syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-012-9898-3

A transient increase in the activity of Src-family kinases induced by cell detachment delays anoikis of intestinal epithelial cells

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-012-9898-3

Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482128

Gemcitabine-induced thrombotic microangiopathy: a systematic review

31 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-012-9898-3

Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23179336

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23179336

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-012-9898-3

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference